Back to Clinical Trials Directory
CMDN Open Science Initiative

China Multiple Myeloma Clinical Trials Open Dataset

Empowering open scientific research and patient navigation. CMDN extracts, normalizes, and cleans active multiple myeloma clinical trial records in China into a standardized, machine-readable dataset available under CC BY 4.0.

Trial Records

71 trials

70 actively recruiting

Study Centers in China

338 centers

across 31 provincial regions

Overseas Study Centers

200 centers

sites of international multi-center studies

Dataset Snapshot Date

2026-09-04T12:13:20.050Z

Download and Access

Format: JSON | License: Creative Commons Attribution 4.0 International

Download JSON

Programmatic Access Example (cURL)

# Direct download via cURL
curl -s https://chinamyeloma.org/data/clinical-trials.json | jq '.trials | length'

Field Specification

The public dataset exposes standardized facts essential for comparative research, patient matching, and graph indexing.

Field (字段)Type (类型)Description (中文说明)Example (示例)
idstringStable CMDN record identifier0Bh4XLbDLcThpJZRHFRY
cde_idstring?NMPA CDE registration number (CTR + 8 digits)CTR20231707
registry_idstringPreferred official registry identifierCTR20231707
registry_systemstringRegistry system code (CDE_CTR, CHICTR, CLINICALTRIALS_GOV)CDE_CTR
cross_registry_ids{system,value,url?}[]The same study’s identifiers in other public registries, with directly accessible verification URLs (beyond the primary registry_id)[{"system":"CLINICALTRIALS_GOV","value":"NCT07518186","url":"https://clinicaltrials.gov/study/NCT07518186"}]
registry_statusstringRegistration tier: cde_registered / international_registry_only / other_identifier_only / unregisteredcde_registered
titlestringOfficial protocol title as registered评估注射用…耐受性的 I 期临床试验
status_codestringNormalized recruitment status coderecruiting
phase_codestringNormalized clinical phase codephase_1
targetstringPrimary target or mechanism of actionBCMA、GPRC5D、CD38
therapy_typesstring[]Modality classification (CAR-T, bispecific, monoclonal antibody, small molecule)["CAR-T"]
populationstringTarget population tier (synthesized by CMDN from public filings; not an official CDE field)复发难治
locationsstring[]Study centers after de-duplication and branch-campus normalization[ "四川大学华西医院", "西京医院" ]
locations_countnumberNumber of participating study centers15
locations_count_chinanumberStudy centers resolvable to a Chinese provincial-level region (incl. HK/Macau/Taiwan)22
locations_count_overseasnumberOverseas sites of international multi-center studies200
urlstringCanonical CMDN page for this studyhttps://chinamyeloma.org/zh/clinical-trials/…
source_document_typestringType of the archived source documentcde_registration
source_pdf_urlstringDirect link to the archived source filing (PDF); no login or token requiredhttps://chinamyeloma.org/registry/cde/CTR20231707.pdf
updated_atstringTimestamp of the most recent CMDN reconciliation2026-09-03T…

Data Sources & Curation Methodology

1. Primary Extraction: Records originate exclusively from authorized public registries including the NMPA CDE Drug Clinical Trial Information Platform and WHO-recognized primary registries.

2. Hospital Normalization: Raw hospital records often contain branch campuses or inconsistent naming. CMDN applies a rule-based mapping dictionary ensuring accurate provincial hub attribution.

3. Population Stratification: Target patient cohorts are classified across standard hematologic trajectories (Newly Diagnosed, Relapsed/Refractory, Maintenance) based on verified inclusion criteria.

4. Counting Conventions: All trial and center counts on this site read from the dataset’s top-level summary field; individual pages never recompute them. "Trial records" covers every entry including terminated and completed studies, while "recruiting" counts only status_code = recruiting. Center counts deduplicate normalized institution names — raw filings contain trailing punctuation, aggregate rows and pure summary phrases that would otherwise be miscounted as distinct hospitals. "Study centers in China" are those resolvable to a provincial-level region (including Hong Kong, Macau and Taiwan); all others count as overseas centers. Both cover recruiting studies only.